GOTHENBURG, Sweden, September 17, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary […]
GOTHENBURG, Sweden, September 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the company has terminated
GOTHENBURG, Sweden, August 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report
GOTHENBURG, Sweden, July 30, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announced today that the company has appointed
GOTHENBURG, Sweden, July 16, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces results from two preclinical studies
GOTHENBURG, Sweden, July 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that an external committee of
GOTHENBURG, Sweden, June 12, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that Magnus Hurst, Chief Financial
GOTHENBURG, Sweden, May 24, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company has signed
Today on May 8, 2024 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its annual general meeting
GOTHENBURG, Sweden, May 8, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report
